— PUBLICATIONS —

Liste des publications GINECO - Cancer Ovaire 2017


 

  • ARIEL 3 – Article (Lancet)
    R.L. Coleman
    Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet - Juin 2017 (réf. PubMed : PMID: 28916367 - PMCID: PMC5901715 - DOI: 10.1016/S0140-6736(17)32440-6)
  • ICON 7 – Article (Annals of Oncology)
    S.B. Park
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient versus clinician reported incidence and severity of neurotoxicity in the ICON7 trial
    Annals of Oncology - Septembre 2017 (réf. PubMed : PMID: 29117336 - DOI: 10.1093/annonc/mdx491)
  • SOLO2 – Article (Lancet Oncology)
    E. Pujade-Lauraine
    Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet Oncology - Juillet 2017 (réf. PubMed : PMID: 28754483 - DOI: 10.1016/S1470-2045(17)30469-2)
  • TMRG – Article (Annals of Oncology)
    N. Chiannilkulchai
    Networking for ovarian rare tumors: a significant breakthrough improving disease management.
    Annals of Oncology - Juin 2017 (réf. PubMed : PMID: 28398524 - DOI: 10.1093/annonc/mdx099)
  • ESSAI SYMPTOM BENEFIT – Article (The Oncologist)
    F.T. Roncolato
    Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
    The Oncologist - Septembre 2017 (réf. PubMed : PMID: 28596446 - DOI: 10.1634/theoncologist.2017-0047)
  • ESSAI AURELIA – Article (Annals of Oncology)
    F.T. Roncolato
    Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
    Annals of Oncology - Juin 2017 (réf. PubMed : PMID: 28595285 - DOI: 10.1093/annonc/mdx229)
  • ESSAI AURELIA – Article (Annals of Oncology)
    A. Bamias
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Annals of Oncology - Mai 2017 (réf. PubMed : PMID: 28481967 - DOI: 10.1093/annonc/mdx228)
  • ESSAI Symptom benefit – Article (The Oncologist)
    F.T. Roncolato
    Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
    The Oncologist - Juin 2017 (réf. PubMed : PMID: 28596446 - DOI: 10.1634/theoncologist.2017-0047)
  • Conference of the Gynecologic Cancer InterGroup – Article (European Journal of Cancer)
    F. Joly
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
    European Journal of Cancer - Juin 2017 (réf. PubMed : PMID: 28448857 - DOI: 10.1016/j.ejca.2017.03.019)
Haut de page

Modifié le 21-06-2018 14:06